Oncology News | pharmaphorum

News

J&J builds case for earlier Tecvayli use in multiple myeloma

Johnson & Johnson has added another piece to the data behind its effort to move Tecvayli into earlier-line therapy for multiple myeloma.

News

JPM: AbbVie pays $650m upfront for RemeGen cancer drug

AbbVie joins the ranks of companies developing cancer drugs that target both PD-1 and VEGF, via a $5.6bn licensing deal with China's RemeGen.

News

Perlmutter's Eikon follows the IPO trail

Two more biotechs have joined the Nasdaq IPO queue, namely Roger Perlmutter's cancer biotech Eikon and hair loss drug developer Veradermics.

News

Now Iktos teams up with Pierre Fabre in oncology

As Servier announces its partnership with Paris, France-based Iktos, now Pierre Fabre Laboratories has revealed an integrated collaboration with Iktos

News

$100 bill with missing puzzle pieces to be inserted

Parabilis scores $305m in bumper biofinancing week

Money has flooded into biotechs this week, with Parabilis raising $305m and five other start-ups closing nine-figure private rounds.

News

Spinning top in black and white, revolving

Report says MSD is in talks to buy Revolution Meds

MSD is rumoured to be in talks to buy Revolution Medicines and its KRAS inhibitor pipeline in a deal that could be worth up to $32 billion.

J&J builds case for earlier Tecvayli use in multiple myeloma

JPM: AbbVie pays $650m upfront for RemeGen cancer drug

Perlmutter's Eikon follows the IPO trail

Now Iktos teams up with Pierre Fabre in oncology

Parabilis scores $305m in bumper biofinancing week

Report says MSD is in talks to buy Revolution Meds

JPM2026: AI diagnostics and translational research, with And...

How to meet your physicians where they are online

News

Editor's Picks